company background image
6622 logo

Zhaoke Ophthalmology SEHK:6622 Stock Report

Last Price

HK$1.40

Market Cap

HK$764.6m

7D

-4.8%

1Y

-65.1%

Updated

14 Jun, 2024

Data

Company Financials +

Zhaoke Ophthalmology Limited

SEHK:6622 Stock Report

Market Cap: HK$764.6m

6622 Stock Overview

An ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, and Hong Kong.

6622 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Zhaoke Ophthalmology Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zhaoke Ophthalmology
Historical stock prices
Current Share PriceHK$1.40
52 Week HighHK$4.50
52 Week LowHK$1.38
Beta0.96
1 Month Change-10.26%
3 Month Change-12.50%
1 Year Change-65.09%
3 Year Change-88.08%
5 Year Changen/a
Change since IPO-90.22%

Recent News & Updates

Recent updates

Shareholder Returns

6622HK PharmaceuticalsHK Market
7D-4.8%-1.8%-1.8%
1Y-65.1%-6.8%-3.7%

Return vs Industry: 6622 underperformed the Hong Kong Pharmaceuticals industry which returned -4.9% over the past year.

Return vs Market: 6622 underperformed the Hong Kong Market which returned -2.6% over the past year.

Price Volatility

Is 6622's price volatile compared to industry and market?
6622 volatility
6622 Average Weekly Movement3.9%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement7.2%
10% most volatile stocks in HK Market15.3%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 6622 has not had significant price volatility in the past 3 months.

Volatility Over Time: 6622's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017313Benjamin Liwww.zkoph.com

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, and Hong Kong. It is developing various drugs that cover ophthalmic indications, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited.

Zhaoke Ophthalmology Limited Fundamentals Summary

How do Zhaoke Ophthalmology's earnings and revenue compare to its market cap?
6622 fundamental statistics
Market capHK$764.59m
Earnings (TTM)-HK$414.54m
Revenue (TTM)HK$20.19m

37.9x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6622 income statement (TTM)
RevenueCN¥18.75m
Cost of RevenueCN¥4.50m
Gross ProfitCN¥14.25m
Other ExpensesCN¥399.29m
Earnings-CN¥385.04m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.71
Gross Margin75.98%
Net Profit Margin-2,053.54%
Debt/Equity Ratio10.1%

How did 6622 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.